Cumulative frequency of adverse laboratory events among children and adolescents with SCA treated at MTD in the phase 1/2 HUG-KIDS study21
| Toxicity . | Toxicity definition . | Percentage of patients . | Percentage of visits . |
|---|---|---|---|
| Neutropenia | 2.0 × 109/L | 67 | 5.2 |
| Reticulocytopenia | 80 × 109/L unless hemoglobin ≥ 9.0 g/dL | 42 | 1.6 |
| Anemia | 20% decrease or < 4.5 g/dL | 32 | 1.1 |
| ALT elevation | 2× upper limit of normal | 13 | 0.4 |
| Thrombocytopenia | 80 × 109/L | 8 | 0.3 |
| Creatinine elevation | 50% increase and > 1.0 mg/dL | 0 | 0.0 |
| Toxicity . | Toxicity definition . | Percentage of patients . | Percentage of visits . |
|---|---|---|---|
| Neutropenia | 2.0 × 109/L | 67 | 5.2 |
| Reticulocytopenia | 80 × 109/L unless hemoglobin ≥ 9.0 g/dL | 42 | 1.6 |
| Anemia | 20% decrease or < 4.5 g/dL | 32 | 1.1 |
| ALT elevation | 2× upper limit of normal | 13 | 0.4 |
| Thrombocytopenia | 80 × 109/L | 8 | 0.3 |
| Creatinine elevation | 50% increase and > 1.0 mg/dL | 0 | 0.0 |
SCA indicates sickle cell anemia; MTD, maximum tolerated dose; HUG-KIDS, prospective National Heart, Lung and Blood Institute–sponsored pediatric trial; and ALT, alanine aminotransferase.